Vascular remodeling is a series of structural changes in blood vessels. Therefore, it may be conceivable that any humoral factors and physical forces acting on the vascular wall are involved in the remodeling processes. Cells in the vascular wall respond to the humoral and physical factors and may induce extracellular matrix, cell adhesion molecules and other humoral factors. They even grow so that cellular and noncellular components deviate from the normal population.
nents deviate from those of the normal population.
NO is produced by three distinct enzymes, the NO synthases (NOS):1) type I, II, and III. All three enzymes are present in the vascular wall. Type I (neuronal NO synthase) is localized in certain postganglionic parasympathetic nerves in brain vessels. Type II (inducible NO synthase) is expressed in inflammatory states. Bacterial lipopolysaccharide and many cytokines are capable of inducing these enzymes in the endothelium, smooth muscles, macrophages, neutrophils and fibroblasts. Type III is localized in the endothelium. Three enzymes catalyze the respective reactions from L-arginine and O2 to L-citrulline and NO.
NO has a variety of biological functions, including inhibition of platelet adhesion and aggregation and smooth muscle relaxation. Among the numerous components of the vascular wall, we focus herein on NO, pressure and smooth muscle growth. As discussed below, NO and pressure have reciprocal interactions and both affect smooth muscle growth directly and indirectly. Garg and Hassid (1989) were the first to show the inhibitory effects of NO donors, including nitroprusside, S-nitroso-N-acetylpenicillamine, and isosorbide dinitrate, on cultured vascular smooth muscle cells.2) They also demonstrated that the membrane-permeable cGMP analogue, 8-Br-cGMP, is an effective growth inhibitor. We (1990) showed that NO gas inhibits vascular smooth muscle growth.
DIRECT INHIBITION OF SMOOTH MUSCLE GROWTH BY NO
3) It was demonstrated that a single treatment with NO gas was not sufficient to produce the inhibitory effects and that multiple treatments were necessary. Mooradian et al. (1995) carried out interesting experiments in which they examined a series of NO-donors with different biological half lives in aqueous medium.4) They demonstrated that only NO-donors with a half life of longer than 15min effectively inhibited smooth muscle cell growth. Taken together, these observations indicate that both sufficient time and concentrations are required for the inhibition of smooth muscle growth.
As shown in the table, SNP, SNAP, ISDN, nitroglycerin, DEA/NO, PAPA/NO, SPER/NO and DPTA/NO liberate intracellular NO. NO activates soluble guanylyl cyclase, leading to cGMP production in cells. 8-Br-cGMP is a membrane permeable cGMP analogue. L-arginine, which presumably acts as a substrate for NO synthase, has inhibitory effects on neointima formation in balloon injury models. Two weeks after balloon injury, animals that received both oral and local administration of L-arginine showed suppression of neointimal proliferation.5,6) Atrial natriuretic peptide activates a particulate guanylyl cyclase and increases intracellular cGMP. Ramipril is an inhibitor of angiotensin converting enzyme (ACE) that not only converts angiotensin I to angiotensin II, but Jpn Heart J July 1996 to a three-way rotary valve, sphygmomanometer and pressure valve. While the He gas was being pumped in, no pre-packed room air was released. As predicted by Boyle-Charles' law, the partial pressures of the gases contained in the flask, including oxygen, nitrogen and carbon dioxide, were constant. Employing the above experimental system, we have examined whether pressure alone can cause vascular remodeling, that is growth of smooth muscle cells.17) Pressure (40-120mmHg) promoted cell proliferation and DNA synthesis in a pressure-dependent manner. Pressure-induced DNA synthesis was inhibited by the phospholipase C inhibitor 2-nitro-4-carboxyphenyl-N, Ndephenylcarbamate, protein kinase C inhibitors, and the tyrosine kinase inhibitor tyrphostin 1. Pure pressure increased IP3 and intracellular Ca2+ in a pressuredependent manner. The increases in both IP3 and intracellular Ca2+ were significantly inhibited by the phospholipase C inhibitor. These data reveal a novel cellular mechanism whereby pressure directly regulates DNA synthesis in vascular smooth muscle cells, possibly via activation of PLC and protein kinase C.
DIRECT INHIBITION OF NO RELEASE FROM ENDOTHELIAL CELLS BY PRESSURE
Panza et al18) and Linder et al19) reported that endothelium-dependent vascular relaxation in patients with hypertension is abnormal. In the lungs of control subjects, NOS was expressed at a high level in the vascular endothelium of all types of vessels. In contrast, little or no expression of the enzyme was found in the vascular endothelium of pulmonary arteries with severe histologic abnormalities in patients with pulmonary hypertension.20) These clinical observations indicate that defects in the L-arginine-NO pathway are associated with hypertension.
Other groups have not, however, observed defects in acetylcholine-stimulated responses to EDRF associated with hypertension.21) These investigators used isolated blood vessels to conduct an in vitro study. Cockcroft et al measured forearm blood flow by plethysmography during infusion of vasodilators into the brachial arteries of control subjects and hypertensive patients. It was demonstrated that selective impairment of forearm vasculature responsiveness to muscarinic agonists is not a consistent finding in patients with essential hypertension.22)
The L-arginine-NO pathway defect has, however, been confirmed by other researchers using different approaches. Platelets from hypertensive patients produce less NO than do those of normal subjects.23) When the responses to N monomethyl-L-arginine (LNMMA) and noradrenaline were compared between hypertensive and normotensive subjects, the response to LNMMA was significantly lower in the hypertensives, whereas there was no statistical difference in noradrenaline responsiveness between the two groups.24) This suggests that hypertensive patients possess either reduced sensitivity to NOS inhibitors or that NO production is diminished. Panza et al also investigated the reduced efficiency of the L-arginine-NO pathway in hypertensive patients. In normal humans, the availability of substrate for NO production is a rate-limiting step in endotheliumdependent vascular relaxation. In contrast, increased availability of the NO precursor does not modify endothelium-mediated vasodilation in hypertensive patients. These findings provide further evidence of a defect in the endotheliumderived NO system in the setting of hypertension. Panza and colleagues also demonstrated that the defect is not at the level of muscarinic receptors nor does it involve an intracellular signal transduction specific to acetylcholine. Patients with essential hypertension have impaired endothelium-dependent vasodilator responses to both acetylcholine and bradykinin. These findings indicate that the endothelial dysfunction demonstrated in this condition is not related to a specific defect in a single intracellular signal-transduction pathway, but rather suggest a relatively nonspecific abnormality of endothelial vasodilator function. 25) We have examined the effects of pressure on NO release from human umbilical vein endothelial cells stimulated with histamine, which induces NO production. To date, the L-arginine-NO pathway is the only mechanism identified as being responsible for endogenous production of nitrite and nitrate in a culture system. If bacteria are present, the situation becomes more complex. Pseudomonas aeruginosa, for example, is capable of producing NO via nitrite reductase using nitrite as substrate.26) Hishikawa et al found that pressure loading reduces NO production/release from cultured human umbilical vein endothelial cells.16) The pressure-induced inhibition of NO release was found to be a reversible phenomenon, suggesting that the effect is not due to irreversible pressure damage to the cells.
It has been shown that increased intraluminal pressure causes vasoconstriction.27,28) We speculate that one of the factors responsible for this phenomenon is the pressure-induced inhibition of NO release. We believe that pressure-inhibited NO release is also relevant to the defect observed in hypertensive patients. Nonspecific inhibition of the L-arginine-NO pathway in hypertensive patients is consistent with the notion that pressure, by itself, inhibits NO production/release from endothelial cells. Reducing blood pressure with medication shifts the LNMMA response nearer to that seen in healthy subjects .29) We demonstrated that administering L-arginine intravenously to hypertensive patients normalizes blood pressure. Under the same experimental conditions , we observed that patients with essential hypertension excreted urinary nitrate to an extent similar to that of normal subjects during L-arginine infusion .30) These results suggest that treatment of hypertension may tend to normalize NO mediated vasodilatation . Henriksen made a crucial observation; follow-up studies after 6-18 months of anti-hypertensive treatment indicated that the vasoconstrictor response as well as Jpn Heart J July 1996 minimal vascular resistance normalize, whereas the distensibility of papaverine relaxed arterioles remains unaltered in hypertensive patients. These results indicate that the arteriolar smooth muscle cells of hypertensive patients undergo reversible hypertrophy, whereas the reduced distensibility of the resistance vessels is due to irreversible structural changes.31) These studies clearly demonstrate that hypertensive patients do not have irreversible defects in the L-arginine-NO pathway. The reduced NO release in hypertensives, if present, may result from functional reversible changes in the L-arginine-NO pathway. These lines of evidence are consistent with our in vitro observation that high transmural pressure is a cause, not a consequence, of diminished function of the L-arginine-NO pathway in elevated pressure.
POSSIBLE INDIRECT EFFECT OF NO ON SMOOTH MUSCLE GROWTH VIA CHANGES IN SYSTEMIC BLOOD PRESSURE IN VIVO
Well established pharmacological evidence indicates that inhibition of NOS increases blood pressure in humans32) as well as in experimental animals. Knock-out mice, which are deficient in type III NOS, have elevated blood pressure,34) a finding which establishes the role of NO in lowering blood pressure in vivo. These lines of genetic evidence indicate that blood pressure rises if the Larginine-NO pathway is disrupted. These observations do not establish that the cause of hypertension is a deficiency of NOS. We cannot, however, exclude the possibility that a fraction of hypertensive patients lack type III NOS. Deng (1995) made the interesting observation that the type II NOS locus, rather than type I, is a potential modulator of blood pressure in the Dahl saltsensitive rat. Alleles of the inducible NOS locus cosegregated in a highly significant manner with blood pressure in an F2 population derived from a cross of inbred Dahl salt-sensitive rats with Milan normotensive rats.35) This finding raises the possibility that the type II NOS is involved in physiological blood pressure regulation besides well established immune function.
POSSIBLE EFFECT OF VASCULAR REMODELING ON BLOOD PRESSURE
Aortic stiffness increases with aging, as blood pressure increases, and with pathological changes such as atherosclerosis. This increased stiffness leads to an increase in systolic blood pressure and a decrease in diastolic blood pressure , as well as an increase in left ventricular afterload, and must be considered a major pathophysiological factor in systolic hypertension.36) 
